surufatinib   Click here for help

GtoPdb Ligand ID: 9769

Synonyms: HMPL-012 | HMPL012 | KDR-IN-1 | Sulanda® | VEGFR2 inhibitor [WO2011060746]
Approved drug
surufatinib is an approved drug (China (2020))
Compound class: Synthetic organic
Comment: Surufatinib is an oral tyrosine kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, to inhibit key angiogenic and immune pathways in solid tumours. Surufatinib's chemical structure is claimed in patent WO2011060746, and its use as a potential anti-angiogenic agent is included [1]. In this patent it is referred to as 'Compound of Formula A'.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 120.62
Molecular weight 480.19
XLogP 2.96
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN(CCNS(=O)(=O)Cc1cccc(c1)Nc1nccc(n1)Oc1ccc2c(c1)cc([nH]2)C)C
Isomeric SMILES CN(CCNS(=O)(=O)Cc1cccc(c1)Nc1nccc(n1)Oc1ccc2c(c1)cc([nH]2)C)C
InChI InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
InChI Key TTZSNFLLYPYKIL-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Surufatinib was progressed to Phase 3 evaluations in neuroendocrine tumours (NET), and it was advanced for other solid tumours. In April 2020 the FDA granted Fast Track Designation for surufatinib for the treatment of pancreatic and extra-pancreatic NET. First clinical approval was granted in China in December 2020, which indicated surufatinib as a treatment for late-stage, well-differentiated, extra-pancreatic NET. The US FDA rejected Hutchmed's application for US approval in May 2022, stating that data from a multi-regional clinical trial would be required for FDA approval.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02589821 Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Phase 3 Interventional Hutchison Medipharma Limited
NCT02588170 Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors Phase 3 Interventional Hutchison Medipharma Limited
NCT02549937 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors Phase 1/Phase 2 Interventional Hutchison Medipharma Limited
NCT03873532 A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients Phase 2/Phase 3 Interventional Hutchison Medipharma Limited